Integrated testing for TB and COVID-19

Emily L MacLean; Luz Villa-Castillo; Morten Ruhwald; César Ugarte-Gil; Madhukar Pai

doi:10.1016/j.medj.2022.02.002

Integrated testing for TB and COVID-19

Med. 2022 Mar 11;3(3):162-166. doi: 10.1016/j.medj.2022.02.002. Epub 2022 Feb 11.

Authors

Emily L MacLean^{1

2}, Luz Villa-Castillo³, Morten Ruhwald⁴, César Ugarte-Gil^{3

5}, Madhukar Pai^{1

2}

Affiliations

¹ Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
² McGill International TB Centre, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
³ Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia Lima, Peru.
⁴ FIND, Geneva, Switzerland.
⁵ School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.

Abstract

Integrated testing for TB and COVID-19 may help find those TB patients who are not accessing care in the context of the COVID-19 pandemic. Some molecular platforms with assays for both diseases are already commercially available; however, integrated testing approaches need to be systematically evaluated to ensure their appropriate implementation.

MeSH terms

COVID-19*
Humans
Pandemics
SARS-CoV-2